Zhou Jichun, Wu Qingliang, Lin Xixi, Zhu Ziyu, Hu Yiqiu, Guo Zijie, Wang Shengkangle, Wang Linbo, Ruan Shanming, Luo Mingpeng
Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, China.
Gland Surg. 2025 Jul 31;14(7):1213-1229. doi: 10.21037/gs-2025-100. Epub 2025 Jul 28.
Breast-conserving surgery (BCS) is widely used for ductal carcinoma in situ (DCIS), but ipsilateral breast tumor recurrence (IBTR) remains a significant clinical challenge, highlighting the need for reliable predictive models to guide personalized treatment strategies. This study aims to fill the gap by developing a predictive model for IBTR in DCIS patients who have undergone BCS.
A cohort of 40,770 DCIS patients who underwent BCS between 2000 and 2008 was identified from the Surveillance, Epidemiology, and End Results dataset. Chi-squared tests and logistic regression analyses were conducted to identify significant predictive factors for IBTR. These variables were incorporated into nomograms predicting the 5- and 10-year recurrence probabilities. The model was then used to categorize patients into risk groups.
The nomograms demonstrated good calibration and discriminative ability for predicting 5- and 10-year IBTR probabilities. Patients were stratified into extremely high- and low-risk groups. Among patients receiving adjuvant radiotherapy, those in the standard-risk group showed significantly lower recurrence rates compared to the extremely high-risk group (P<0.001). For the extremely low-risk group, no significant difference in recurrence risk was observed between patients who received adjuvant radiotherapy and those who did not (P=0.065).
Patients with a recurrence rate above 10% were classified as extremely high-risk and may benefit from intensified treatment. Conversely, patients with a recurrence rate below 5% were considered extremely low-risk, suggesting that treatment could be safely de-escalated.
保乳手术(BCS)广泛应用于导管原位癌(DCIS),但同侧乳腺肿瘤复发(IBTR)仍然是一项重大的临床挑战,这凸显了需要可靠的预测模型来指导个性化治疗策略。本研究旨在通过为接受BCS的DCIS患者开发IBTR预测模型来填补这一空白。
从监测、流行病学和最终结果数据集中识别出2000年至2008年间接受BCS的40770例DCIS患者队列。进行卡方检验和逻辑回归分析以确定IBTR的显著预测因素。这些变量被纳入预测5年和10年复发概率的列线图中。然后使用该模型将患者分为风险组。
列线图在预测5年和10年IBTR概率方面显示出良好的校准和判别能力。患者被分为极高风险组和低风险组。在接受辅助放疗的患者中,标准风险组的复发率明显低于极高风险组(P<0.001)。对于极低风险组,接受辅助放疗的患者与未接受辅助放疗的患者之间复发风险无显著差异(P=0.065)。
复发率高于10%的患者被归类为极高风险,可能从强化治疗中获益。相反,复发率低于5%的患者被认为是极低风险,这表明治疗可以安全地降级。